NCT02586233已完成1 期
A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 106
- 试验地点
- 55
- 主要终点
- Summary of Treatment-Emergent Adverse Event Reported by >10% of Participants Following Ascending Doses of DS-1040b and a Placebo in Participants With Acute Ischemic Stroke
研究概览
简要总结
This is a Phase 1b/2, double-blind (study participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in participants with Acute Ischemic Stroke (AIS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has a clinical diagnosis of acute ischemic stroke (including lacunar stroke/infarct) supported by computed topography or magnetic resonance imaging to rule out alternative cause for presenting symptoms
- •Has onset of stroke symptoms within 4.5 to 12 hours before initiation of study drug administration - for subjects with a stroke upon waking, time of symptom onset is the last time the subject was known to be well
- •Has a NIHSS score of ≥ 2 (for Cohorts 1-5) and ≥ 5 (for Cohort 6)
- •Has Low dose heparin or low molecular weight heparin at a preventive dose are allowed from 24 hours after treatment start completion and after confirmation of no intracranial bleeding on the 24-hours repeat brain imaging.
- •Is a Cohort 6 participant who is treated or anticipated to be treated with intra-arterial therapy (IAT) for ischemic stroke at the time of randomization (for enrollment in the IAT subgroup)
- •Has given written informed consent to participate in the study prior to participating in any study-related procedures - depending on country-specific practice, written informed consent may be acceptable from legally authorized representative
- •Has given a separate written informed consent for collecting a blood sample for genotyping
排除标准
- •Is a Cohort 1-5 participant who has been treated or is going to be treated with tissue plasminogen activator (tPA) and/or endovascular thrombectomy during current stroke
- •Is a Cohort 6 participant treated or anticipated to be treated with tPA during current stroke
- •Has evidence of intracranial hemorrhage on non-contrast computed tomography (CT/CAT) scan or magnetic resonance imaging (MRI)
- •Has symptoms of subarachnoid hemorrhage, even with normal imaging
- •Has an Alberta Stroke Program Early CT Score (ASPECTS) <6
- •Has prior non-traumatic intracranial hemorrhage (excluding microhemorrhages observed in imaging)
- •Has known arteriovenous malformation or aneurysm
- •Has evidence of active bleeding
- •Has platelet count less than 100,000
- •Has International Normalized Ratio greater than 1.7
- •Has used unfractionated heparin within 24 hours prior to treatment and has an elevated partial thromboplastin time
- •Has used a non-vitamin K antagonist oral anticoagulant such as dabigatran, rivaroxaban, apixaban, or other factor Xa inhibitors within 24 hours before treatment
- •Has used fondaparinux or low molecular weight heparin at an anticoagulation dose within 24 hours prior to treatment
- •Has anticipated use of an anticoagulation dose of heparin, or fondaparinux or low molecular weight heparin, or nonvitamin K antagonist oral anticoagulant such as dabigatran, rivaroxaban, apixaban, or other factor Xa inhibitors within 48 hours after completion of study drug treatment (low dose heparin or low molecular weight heparin at a preventive dose are allowed from 24 hours after treatment completion and after confirmation of no intracranial bleeding on the 24 hours repeat brain imaging. In Cohort 6, heparin treatment associated with IAT is allowed.)
- •Has blood pressure > 185/110 mmHg, or requires aggressive medication to maintain blood pressure below this limit (routine medical treatment including IV drug treatment is allowed to lower the blood pressure below this limit)
- •Has had intracranial surgery, clinically significant head trauma (in the opinion of Principal Investigator), Alteplase treatment, or a previous stroke within 1 month
- •Has had major surgery within 14 days
- •Has had gastrointestinal or genitourinary bleeding in the last 21 days
- •Has had a lumbar puncture (or epidural steroid injection) within 14 days
- •Has had a preexisting disability classified by modified Rankin Scale (mRS) > 2
- •Has an estimated glomerular filtration rate < 60 mL/min/1.73 m^2
- •Has baseline hemoglobin < 10.5 g/dL
- •Has a positive pregnancy test
- •Is currently participating in another investigational study or has participated in an investigational drug study within 30 days or 5 half-lives of that investigational drug prior to administration of the study drug
- •Is an employee or an immediate family member of an employee of the Sponsor, the Contract Research Organization (CRO), or the Site
- •Has any other condition the investigator determines would preclude participation in the study
研究组 & 干预措施
DS-1040b
Experimental
Participants who will be randomized to receive intravenous (IV) infusion of DS-1040b ranging from 0.6 mg to 9.6 mg.
干预措施: DS-1040b (Drug)
Placebo
Placebo Comparator
Participants who will be randomized to receive intravenous (IV) infusion of placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Summary of Treatment-Emergent Adverse Event Reported by >10% of Participants Following Ascending Doses of DS-1040b and a Placebo in Participants With Acute Ischemic Stroke
时间窗: Baseline up to 90 days post last dose, up to 3 years 11 months
Treatment-emergent adverse event (TEAE) is defined as an adverse event that emerges during the treatment period (from first dose date until 30 days after the last dosing date), having been absent at predose; or reemerges during treatment, having been present at baseline but stopped prior to treatment; or worsens in severity after starting treatment relative to the pre-dose state, when the adverse event is continuous.
次要结局
- Summary of Pharmacokinetic (PK) Parameter Maximum (Peak) Observed Plasma Concentration (Cmax) of DS-1040b Following Ascending Doses in Participants With Acute Ischemic Stroke(Predose, 0.5, 3, 6, 9, 12, 24, 48, 72, and 96 hours postdose)
- Summary of Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve From Zero to Last Quantifiable Concentration Sampling Point (AUClast) of DS-1040b Following Ascending Doses in Participants With Acute Ischemic Stroke(Predose, 0.5, 3, 6, 9, 12, 24, 48, 72, and 96 hours postdose)
- Summary of Activated Form of Thrombin-activatable Fibrinolysis Inhibitor (TAFIa) Following Ascending Doses of DS-1040b and a Placebo in Participants With Acute Ischemic Stroke(Baseline and 6 hours postdose)
- Summary of Changes From Baseline at Day 30 in National Institute of Health Stroke Scale (NIHSS) Score Following Ascending Doses of DS-1040b and a Placebo in Participants With Acute Ischemic Stroke(30 days post dose)
- Summary of Pharmacokinetic Parameter Terminal Half-life (t1/2) of DS-1040b Following Ascending Doses in Participants With Acute Ischemic Stroke(Pre-dose, 0.5, 3, 6, 9, 12, 24, 48, 72, and 96 hours post-dose)
- Percentage of Participants With a Modified Rankin Scale (mRS) Score of 0 to 2 Following Ascending Doses of DS-1040b and a Placebo in Participants With Acute Ischemic Stroke(Day 5 (baseline) and Day 90 post dose)
研究者
研究点 (55)
Loading locations...
相似试验
已完成
1 期
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OAOsteoarthritis, KneeNCT05237752LG Chem74
已完成
2 期
Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DMType 2 Diabetes MellitusNCT02581657PhaseBio Pharmaceuticals Inc.37
撤回
1 期
Study to Evaluate the Safety of ATR-04Epidermal Growth FactorPapulopustular RosaceaNCT04731259Azitra Inc.60
撤回
2 期
Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)Chronic Allograft DysfunctionNCT00878761Stromedix, Inc.48
已完成
2 期
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyNon-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyNCT01186861Astellas Pharma Inc205